Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Vascular Malformations 1Skin Diseases, Vascular 1Primary Malignant Peripheral Nerve Sheath Tumors 1Oligodendroglioma 1Neurofibromatoses 1Neurocytoma 1Neoplasms, Neuroepithelial 1NF1 1Melanoma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Liposarcoma, Myxoid 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Ganglioneuroma 1Ganglioglioma 1Central Nervous System Neoplasms 1Astrocytoma 1Arteriovenous Malformations 1

Interventions

Doxorubicin 4pembrolizumab 3Specimen Handling 3toripalimab 2Ifosfamide 2Biopsy 2silmitasertib 1selinexor 1peposertib 1pemigatinib 1pazopanib 1palbociclib 1mirdametinib 1liposomal doxorubicin 1abemaciclib 1X-Rays 1Vincristine 1Trabectedin 1Temozolomide 1Surgical Procedures, Operative 1Radiotherapy 1Quality of Life 1Proton Therapy 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Irinotecan 1Injections 1Histamine H2 Antagonists 1Gemcitabine 1Famotidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Liposarcoma × mirdametinib × Clear all
NCT06843967 2026-05-22

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
54 enrolled
Sarcoma

Liposarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡